Pharmacology of antisense oligonucleotides

Journal of Clinical Ligand Assay

Volumn 23, Issue 1, 2000, Pages 43-49

  Dean, N M ^a   Cooper, S R ^a   Shanahan, W ^a   Taylor, J ^a   Myers, K ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligonucleotides; Drug development; Gene expression; Gene transcription

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

ARTICLE; DRUG RESEARCH; DRUG USE; GENE EXPRESSION REGULATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE;

EID: 0033709677     PISSN: 10811672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Gene therapeutics and gene therapy for cancer
2. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide
3. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides
4. PKC-epsilon is required for mechano-sensitive activation of ERK1/2 in endothelial cells
5. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides
6. Altered mRNA splicing and inhibition of human E-selectin expression by an antisense oligonucleotide in human umbilical vein endothelial cells
7. Antisense oligonucleotides as inhibitors of genes that regulate AP-1: Pharmacology and clinical development
8. Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides
9. Reduction of expression of the multidrug resistance protein, MRP, in human tumor cells by antisense phosphorothioate oligonucleotides
10. Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression
11. Molecular cloning and expression of cDNA for human RNase H
12. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms
13. Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters
14. 2'-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells
15. Specific and stable intron-factor interactions are established early during in vitro pre-mRNA splicing
16. Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides
17. Cooperation of pre-mRNA sequence elements in splice site selection
18. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides
19. Implication of RNA structure on antisense oligonucleotide hybridization kinetics
20. An in vitro mRNA binding assay as a tool for identifying hybridization-competent anti-sense oligonucleotides
21. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries
22. Control of complexity constraints on combinatorial screening for preferred oligonucleotide hybridization sites on structured RNA
23. Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity
24. Selecting effective antisense reagents on combinatorial oligonucleotide arrays
25. Arrays of complementary oligonucleotides for analyzing the hybridization behavior of nucleic acids
26. Tetranucleotide GGGA motif in primary RNA transcripts novel target site for antisense design
27. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides
28. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus
29. Intracellular delivery of oligonucleotides with cationic liposomes
30. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide
31. Efficient transfer of genetic material into mammalian cells using Starbust polyamidoamine dendrimers
32. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine
33. Inhibition of expression of the multidrug resistance-associated P-glycoprotein by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides
34. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides
35. Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells
36. Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy
37. Antisense medicinal chemistry
38. Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity
39. The ups and downs of nucleic acid duplex stability: Structure-stability studies on chemically modified DNA:RNA duplexes
40. Uniformly modified 2'deoxy-2'-fluoro-phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets
41. Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2'-O-propyl modifications
42. Characterization of a potent and specific class of antisense oligonucleotide inhibitors of human PKC-alpha expression
43. Sequence dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H
44. Oligonucleotide conjugates: Alteration of the pharmacokinetic properties of antisense agents
45. Peptide nucleic acids (PNA) and their potential applications in medicine and biotechnology
46. Concept, discovery and development of MMI linkage: Story of a novel linkage for antisense constructs
47. Pharmacokinetics of antisense oligonucleotides
48. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats
49. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice
50. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate
51. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides
52. Inhibition of c-Fos protein expression in rat spinal cord by antisense oligodeoxynucleotide superfusion
53. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides
54. Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo
55. Suppression of Philadelphial leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide
56. Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities
57. Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man
58. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides
59. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey
60. Immune stimulation a class effect of phosphorothioate oligodeoxynucleotides in rodents
61. Identification of an oligodeoxynucleotide sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases
62. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA
63. Safety and efficacy of fomivirsen sodium (ISIS 2922) for CMV retinitis in AIDS patients
64. Fomivirsin safety and efficacy in the treatment of CMV retinitis: A phase 3, controlled multicenter study comparing immediate versus delayed treatment
65. Antisense oligonucleotides as therapeutics for malignant diseases
66. Antisense therapy for cancer
67. A placebocontrolled trial of an ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease